Vasculitis Pipeline Summary

DelveInsight’s, “Vasculitis - Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vasculitis: Understanding

Vasculitis: Overview

Vasculitis comprises a heterogeneous group of disorders characterized by inflammation of blood vessels, potentially leading to tissue and end-organ damage. Clinical manifestations vary depending on the size, location, and type of vessel involved. More than 30 forms of vasculitis have been identified, occurring either as primary systemic diseases or secondary to an underlying condition. The Chapel Hill Consensus Conference (CHCC) nomenclature is widely used to classify vasculitic syndromes. Major categories include large-vessel vasculitis (giant cell arteritis and Takayasu arteritis), medium-vessel vasculitis (Kawasaki disease and polyarteritis nodosa), small-vessel vasculitis (ANCA-associated vasculitis, cryoglobulinemic vasculitis, and IgA vasculitis), and variable-vessel vasculitis such as Behçet disease.

The etiology of vasculitis remains largely unknown, with susceptibility and clinical presentation influenced by genetic, demographic, geographic, infectious, and environmental factors. In large-vessel vasculitis, Takayasu arteritis is strongly associated with HLA-B52, while giant cell arteritis (GCA) is linked to specific HLA class II alleles. Among medium-vessel vasculitides, polyarteritis nodosa (PAN) is strongly associated with hepatitis B infection, whereas Kawasaki disease involves genetic susceptibility and infectious triggers. Small-vessel vasculitides involve diverse immune and genetic mechanisms; ANCA autoantibodies are central to GPA, MPA, and EGPA, while IgA vasculitis is often preceded by infections or environmental exposures. Cryoglobulinemic vasculitis is primarily associated with mixed cryoglobulins and chronic hepatitis C infection, followed by lymphoproliferative and connective tissue disorders. Behçet disease is strongly associated with HLA-B51, with infections and microbiome alterations potentially contributing to immune dysregulation.

The pathology of vasculitis is characterized by inflammation and injury of blood vessels, with mechanisms varying according to vessel size and disease subtype. In large-vessel vasculitis, such as GCA and Takayasu arteritis, inflammation begins in the adventitia and extends through the vessel wall, driven by dendritic cells, CD4 T cells, Toll-like receptors, and genetic factors such as HLA-B52:01. Medium-vessel vasculitis involves immune-complex deposition in hepatitis B-associated PAN, while classic PAN is linked to Th1/Th17 imbalance; Kawasaki disease involves genetic and infectious triggers, with cytokines such as IL-1 and TNF-? contributing to endothelial injury. In small-vessel vasculitis, ANCA-associated vasculitis results from ANCA-mediated neutrophil activation and complement amplification, causing endothelial damage; IgA vasculitis involves deposition of IgA-containing immune complexes, particularly galactose-deficient IgA1, while cryoglobulinemic vasculitis involves immune-complex formation and is frequently associated with chronic hepatitis C and B-cell activation. Behçet disease, a variable-vessel vasculitis, involves dysregulated T cells, NK cells, and neutrophils, resulting in endothelial dysfunction, thrombosis, and inflammatory vascular lesions.

Diagnosis of vasculitis varies by subtype and generally combines clinical evaluation, laboratory tests, imaging, and selective biopsy. GCA is assessed using ESR/CRP, temporal artery biopsy, and imaging such as ultrasound, MRI, or PET; Takayasu arteritis relies mainly on MRA/CTA, with PET helping assess disease activity. PAN is evaluated through inflammatory markers, hepatitis serology, and vascular imaging, while Kawasaki disease is diagnosed clinically with ECG and echocardiography to assess cardiac involvement. ANCA-associated vasculitis is supported by ANCA testing, inflammatory and renal findings, imaging, and biopsy; EGPA additionally features eosinophilia and pulmonary involvement. IgA vasculitis is primarily diagnosed clinically, with urinalysis and biopsy in uncertain cases. Cryoglobulinemic vasculitis requires cryoglobulin testing alongside complement, rheumatoid factor, and viral serology, whereas Behçet disease is diagnosed clinically using established criteria, with imaging used to evaluate organ involvement.

Management of vasculitis depends on the disease subtype and severity, with glucocorticoids, immunosuppressants, and targeted therapies forming the treatment foundation. GCA is primarily treated with glucocorticoids, often with tocilizumab or methotrexate as steroid-sparing agents, while Takayasu arteritis is managed with glucocorticoids and immunosuppressants such as methotrexate, azathioprine, or tocilizumab. Kawasaki disease is treated mainly with IVIG and aspirin, whereas PAN requires glucocorticoids with steroid-sparing therapy, reserving cyclophosphamide for severe disease. Severe GPA/MPA is generally treated with rituximab plus glucocorticoids, with avacopan offering a steroid-sparing option; EGPA may require glucocorticoids, rituximab, cyclophosphamide, or IL-5–targeted therapies. Cryoglobulinemic vasculitis is managed by addressing the underlying cause, particularly hepatitis C, with immunosuppression or plasma exchange for severe disease. IgA vasculitis is usually managed supportively, with glucocorticoids or immunosuppression for significant organ involvement, while Behçet disease is treated according to manifestations using colchicine, glucocorticoids, immunosuppressants, or biologics.

"Vasculitis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasculitis pipeline landscape is provided which includes the disease overview and Vasculitis treatment guidelines. The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve Vasculitis.

Vasculitis Emerging Drugs Chapters

This segment of the Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasculitis Emerging Drugs

BDB-001: Staidson (Beijing) Biopharmaceuticals

BDB-001 is an investigational recombinant human IgG4 monoclonal antibody targeting complement C5a, developed by Staidson (Beijing) Biopharmaceuticals for ANCA-associated vasculitis (AAV). By selectively binding and neutralizing the program has subsequently advanced to a Phase III trial evaluating BDB-001 in combination with cyclophosphamide followed by azathioprine or with rituximab for induction of remission in active AAV. Staidson's pipeline identifies BDB-001 as a monoclonal antibody being developed for ANCA Associated Vasculitis.

Iptacopan: Novartis

Iptacopan is an oral, first-in-class factor B inhibitor developed by Novartis that selectively blocks the alternative complement pathway. It is being investigated in ANCA-associated vasculitis (AAV), particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), in combination with rituximab, with the aim of reducing complement-mediated inflammation, supporting remission, and minimizing glucocorticoid exposure. Iptacopan is not currently approved for AAV, with its approved indications focused on other complement-mediated disorders. Currently, the drug is in Phase II stage of its development for the treatment of ANCA Associated Vasculitis.

FT839: Fate Therapeutics

FT839 is an investigational next-generation, off-the-shelf dual-CAR T-cell therapy developed by Fate Therapeutics for autoimmune diseases, including ANCA-associated vasculitis (AAV). It is engineered to simultaneously target CD19 and CD38, enabling depletion of multiple pathogenic immune-cell populations, including B cells, plasmablasts, plasma cells, and activated T cells. FT839 is currently being evaluated in a Phase I/II basket trial that includes moderate-to-severe AAV, with the goal of assessing its safety, tolerability, and preliminary clinical activity.

Povetacicept: Vertex Pharmaceuticals

Povetacicept is a dual antagonist of BAFF and APRIL, cytokines that play important roles in B-cell activation, differentiation, and survival and contribute to the pathogenesis of various autoimmune diseases. Engineered from a TACI domain, povetacicept demonstrates high binding affinity and potent inhibition of both targets, with clinical studies showing promising efficacy in IgA nephropathy and primary membranous nephropathy. It is also being developed for other serious autoimmune conditions, including autoimmune kidney diseases and autoimmune cytopenias. Currently, the therapy is in Phase I/II stage of its development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.

Further product details are provided in the report……..

Vasculitis: Therapeutic Assessment

This segment of the report provides insights about the different Vasculitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vasculitis
• There are approx. 25+ key companies which are developing the therapies for Vasculitis. The companies which have their Vasculitis drug candidates in the most advanced stage, i.e. Phase III include, Staidson (Beijing) Biopharmaceuticals.

• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasculitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Vasculitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasculitis drugs.

Vasculitis Report Insights

• Vasculitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vasculitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vasculitis drugs?
• How many Vasculitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasculitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasculitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vasculitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Staidson (Beijing) Biopharmaceuticals
• Novartis
• Fate Therapeutics
• Artiva
• AstraZeneca
• NovelMed
• Soligenix
• Vertex Pharmaceuticals
• Resolve Therapeutics
• Nkarta Therapeutics
• Catersian Therapeutics
• Travere Therapeutics
• Kyverna Therapeutics

Key Products

• BDB-001
• Iptacopan
• FT839
• FT819
• AlloNK
• tarperprumig
• NM8074
• SGX-945
• Povetacicept
• RSLV-145
• AZD1656
• NKX019
• Descartes-08
• sparsentan
• KYV-101